Multiple Organ Dysfunction Syndrome clinical trials at University of California Health
2 research studies open to eligible people
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
open to eligible people ages up to 17 years
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
at UC Davis UCSF
COVID-19 Outcome Prediction Algorithm
open to eligible people ages 18 years and up
Severe acute respiratory syndrome coronavirus 2-mediated coronavirus disease (COVID-19) is an evolutionarily unprecedented natural experiment that causes major changes to the host immune system. We propose to develop a test that accurately predicts short- and long-term (within one-year) outcomes in hospitalized COVID-19 patients broadly reflecting US demographics who are at increased risk of adverse outcomes from COVID-19 using both clinical and molecular data. We will enroll patients from a hospitalized civilian population in one of the country's largest metropolitan areas and a representative National Veteran's population.
at UCLA
Our lead scientists for Multiple Organ Dysfunction Syndrome research studies include Mario C. Deng.